Taipei Veterans General Hospital

Department of Pathology and Laboratory Medicine
No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City, Taiwan
11217, R.O.C.
Tel: 02-2875-7449

Sample Information

Patient Name: 許菱倩
Gender: Female
ID No.: A223607288
History No.: 43139066
Age: 47

Ordering Doctor: DOC3016D 江起陸
Ordering REQ.: 0ASMGPY
Signing in Date: 2020/06/04

Path No.: S109-99537
MP No.: F20029
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S109-15670A
Percentage of tumor cells: 40%
Note:

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page
Variant Details	2
Biomarker Descriptions	3
Relevant Therapy Summary	3
Relevant Therapy Details	9

Report Highlights

2 Relevant Biomarkers
8 Therapies Available
103 Clinical Trials

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	Not detected	NTRK1	Not detected
BRAF	Not detected	NTRK2	Not detected
EGFR	***EGFR exon 19 deletion, EGFR p.(T790M) c.2369C>T***	NTRK3	Not detected
ERBB2	Not detected	RET	Not detected
KRAS	Not detected	ROS1	Not detected
MET	Not detected		

Relevant Biomarkers

Indicated **Contraindicated**

Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
EGFR exon 19 deletion epidermal growth factor receptor Tier: IA Allele Frequency: 34.40%	**osimertinib** [1, 2] afatinib + cetuximab **bevacizumab* + erlotinib** [2] **erlotinib + ramucirumab** [2] atezolizumab + bevacizumab + chemotherapy gefitinib + chemotherapy bevacizumab + gefitinib	None	87
EGFR p.(T790M) c.2369C>T epidermal growth factor receptor Tier: IA Allele Frequency: 11.31%	**osimertinib** [1, 2] afatinib + cetuximab **gefitinib** [2]	None	61

Public data sources included in relevant therapies: FDA1, NCCN, **EMA**2, ESMO
Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.
*** Includes biosimilars**

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
EGFR	p.(E746_A750del)	c.2235_2249delGGAATTAAGAGAAGC	COSM6223	chr7:55242464	34.40%	NM_005228.4	nonframeshift Deletion	1962
EGFR	p.(T790M)	c.2369C>T	COSM6240	chr7:55249071	11.31%	NM_005228.4	missense	1999
JAK1	p.(=)	c.2199A>G	.	chr1:65310489	45.41%	NM_002227.3	synonymous	1993
ALK	p.(D1529E)	c.4587C>G	.	chr2:29416366	48.70%	NM_004304.4	missense	1998
ALK	p.(I1461V)	c.4381A>G	.	chr2:29416572	99.90%	NM_004304.4	missense	1997
ALK	p.(=)	c.3375C>A	.	chr2:29445458	48.80%	NM_004304.4	synonymous	1996
FGFR3	p.(=)	c.1953G>A	.	chr4:1807894	99.75%	NM_000142.4	synonymous	1588
PDGFRA	p.(=)	c.939T>G	.	chr4:55133726	40.24%	NM_006206.5	synonymous	1993
PDGFRA	p.(=)	c.1701A>G	.	chr4:55141055	99.89%	NM_006206.5	synonymous	1864
PDGFRA	p.(=)	c.2472C>T	.	chr4:55152040	40.57%	NM_006206.5	synonymous	1999
FGFR4	p.(P136L)	c.407C>T	.	chr5:176517797	99.50%	NM_213647.2	missense	2000
RET	p.(=)	c.2307G>T	.	chr10:43613843	48.22%	NM_020975.4	synonymous	1999
RET	p.(=)	c.2712C>G	.	chr10:43615633	46.67%	NM_020975.4	synonymous	1999

Biomarker Descriptions

EGFR (epidermal growth factor receptor)

Background: The EGFR gene encodes the epidermal growth factor receptor (EGFR) tyrosine kinase, a member of the human epidermal growth factor receptor (HER) family. Along with EGFR/ERBB1/HER1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4 make up the HER protein family[1]. EGFR ligand induced dimerization results in kinase activation and leads to stimulation of oncogenic signaling pathways including the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways. Activation of these pathways promote cell proliferation, differentiation, and survival[2,3].

Alterations and prevalence: Recurrent somatic mutations in the tyrosine kinase domain of EGFR are observed in approximately 10-20% of lung adenocarcinoma and at higher frequencies in never-smoker, female, and in Asian populations with lung cancer[4,5,6,7]. The most common mutations occur near the ATP-binding pocket of the kinase domain and include short in-frame deletions in exon 19 (EGFR exon 19 deletion) and the L858R amino acid substitution in exon 21[8]. These mutations constitutively activate the EGFR kinase resulting in downstream signaling and represent 80% of the EGFR mutations observed in lung cancer. A second group of recurrent activating mutations that are less common include E709K, G719X, S768I, L861Q, and short in-frame insertions in exon 20[9,10,11,12]. EGFR activating mutations in lung cancer tend to be mutually exclusive to KRAS activating mutations[13]. Although these variants are common in lung cancer, they are rare in other cancer types. In glioblastoma, recurrent activating EGFR mutations in the extracellular domain include R108K, A289V and G598V[8,14]. The recurrent focal amplification of the EGFR gene leads to an increase in expression in several cancer types. EGFR is amplified in up to 30% of glioblastoma, 12% of esophageal cancer, 10% of head and neck cancer, 5% of bladder cancer, and 5% of lung squamous cell carcinoma[5,6,7,14,15]. Deletion of exons 2-7 encoding the extracellular domain of EGFR (EGFRvIII) results in overexpression of a ligand-independent constitutively active protein which is frequently observed in glioblastoma and has been shown to lead to lung cancer development as well as sensitivity to TKIs[16,17,18].

Potential relevance: Erlotinib[19] (2004), afatinib[20] (2013), gefitinib[21] (2015), osimertinib[22] (2015), and dacomitinib[23] (2018) are small molecule TKIs that are FDA approved for non-small cell lung cancer (NSCLC) patients with sensitizing exon 19 deletions and exon 21 L858R mutations. Acquired secondary mutations often confer resistance to first line TKI therapy with the T790M amino acid substitution accounting for 50-60% of cases[8]. Osimertinib is also indicated for NSCLC patients harboring EGFR T790M mutations whose disease has progressed on or after treatment with a first line TKI. EGFR targeting antibodies including cetuximab[24] (2004), panitumumab[25] (2006), and necitumumab[26] (2016) are also under investigation in combination with EGFR-targeting TKIs for efficacy against EGFR mutations. The use of cetuximab in combination with afatinib is currently recommended by the NCCN for patients who have progressed after receiving erlotinib, afatinib, dacomitinib, or gefitinib and chemotherapy[27].

Relevant Therapy Summary

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR exon 19 deletion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
osimertinib	●	●	●	●	● (III)
bevacizumab + erlotinib	✖	●	●	●	● (II)
erlotinib + ramucirumab	✖	●	●	●	✖
afatinib + cetuximab	✖	●	✖	✖	✖
bevacizumab (Allergan) + erlotinib	✖	✖	●	✖	✖

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR exon 19 deletion (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
atezolizumab + bevacizumab + carboplatin + paclitaxel	✖	✖	✖	●	✖
bevacizumab + gefitinib	✖	✖	✖	●	✖
gefitinib + carboplatin + pemetrexed	✖	✖	✖	●	✖
bevacizumab + osimertinib, osimertinib	✖	✖	✖	✖	● (IV)
icotinib hydrochloride	✖	✖	✖	✖	● (IV)
icotinib hydrochloride, icotinib hydrochloride + chemotherapy	✖	✖	✖	✖	● (IV)
icotinib hydrochloride, radiation therapy	✖	✖	✖	✖	● (IV)
bevacizumab (Shanghai Hengrui Pharmaceutical) + chemotherapy, bevacizumab + chemotherapy	✖	✖	✖	✖	● (III)
bevacizumab, atezolizumab, chemotherapy	✖	✖	✖	✖	● (III)
durvalumab, chemotherapy	✖	✖	✖	✖	● (III)
icotinib hydrochloride, chemotherapy	✖	✖	✖	✖	● (III)
icotinib hydrochloride, icotinib hydrochloride + radiation therapy	✖	✖	✖	✖	● (III)
osimertinib, chemotherapy	✖	✖	✖	✖	● (III)
pembrolizumab, chemotherapy	✖	✖	✖	✖	● (III)
anlotinib hydrochloride + icotinib hydrochloride	✖	✖	✖	✖	● (II)
anlotinib hydrochloride, osimertinib	✖	✖	✖	✖	● (II)
atezolizumab, chemotherapy	✖	✖	✖	✖	● (II)
bevacizumab, osimertinib	✖	✖	✖	✖	● (II)
bintrafusp alfa, chemoradiation therapy, durvalumab	✖	✖	✖	✖	● (II)
BPI-7711	✖	✖	✖	✖	● (II)
chemotherapy, atezolizumab, bevacizumab	✖	✖	✖	✖	● (II)
chemotherapy, durvalumab	✖	✖	✖	✖	● (II)
chemotherapy, ramucirumab	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR exon 19 deletion (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
crizotinib + chemotherapy	✖	✖	✖	✖	● (II)
durvalumab, tremelimumab, chemotherapy	✖	✖	✖	✖	● (II)
famitinib, HS-10296	✖	✖	✖	✖	● (II)
icotinib hydrochloride + radiation therapy	✖	✖	✖	✖	● (II)
icotinib hydrochloride + radiation therapy, icotinib hydrochloride	✖	✖	✖	✖	● (II)
nivolumab, ipilimumab	✖	✖	✖	✖	● (II)
osimertinib + radiation therapy	✖	✖	✖	✖	● (II)
osimertinib, bevacizumab	✖	✖	✖	✖	● (II)
osimertinib, osimertinib + chemotherapy	✖	✖	✖	✖	● (II)
osimertinib, radiation therapy	✖	✖	✖	✖	● (II)
osimertinib, ramucirumab	✖	✖	✖	✖	● (II)
osimertinib, savolitinib	✖	✖	✖	✖	● (II)
pembrolizumab + chemotherapy	✖	✖	✖	✖	● (II)
tyrosine kinase inhibitors, radiation therapy	✖	✖	✖	✖	● (II)
ASK120067	✖	✖	✖	✖	● (I/II)
AZD4635 + oleclumab	✖	✖	✖	✖	● (I/II)
CBT-502, anlotinib hydrochloride	✖	✖	✖	✖	● (I/II)
DZD-9008	✖	✖	✖	✖	● (I/II)
EMB01	✖	✖	✖	✖	● (I/II)
icotinib hydrochloride + chemotherapy + radiation therapy	✖	✖	✖	✖	● (I/II)
KP-673	✖	✖	✖	✖	● (I/II)
lazertinib	✖	✖	✖	✖	● (I/II)
U3-1402	✖	✖	✖	✖	● (I/II)
alisertib, osimertinib	✖	✖	✖	✖	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR exon 19 deletion (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
CK-101	✖	✖	✖	✖	● (I)
everolimus + neratinib, neratinib + palbociclib, neratinib + trametinib	✖	✖	✖	✖	● (I)
FCN-411	✖	✖	✖	✖	● (I)
genolimzumab, fruquintinib	✖	✖	✖	✖	● (I)
JNJ-61186372, lazertinib	✖	✖	✖	✖	● (I)
lazertinib, JNJ-61186372	✖	✖	✖	✖	● (I)
nazartinib, trametinib	✖	✖	✖	✖	● (I)
niraparib, osimertinib	✖	✖	✖	✖	● (I)
nivolumab, ipilimumab, radiation therapy	✖	✖	✖	✖	● (I)
osimertinib + radiation therapy, osimertinib	✖	✖	✖	✖	● (I)
osimertinib, necitumumab	✖	✖	✖	✖	● (I)
pirotinib	✖	✖	✖	✖	● (I)
SH-1028	✖	✖	✖	✖	● (I)
telisotuzumab vedotin, osimertinib	✖	✖	✖	✖	● (I)
TNO-155	✖	✖	✖	✖	● (I)
TP-0903	✖	✖	✖	✖	● (I)
tyrosine kinase inhibitors, tyrosine kinase inhibitors + chemotherapy	✖	✖	✖	✖	● (I)

EGFR p.(T790M) c.2369C>T

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
osimertinib	●	●	●	●	● (IV)
afatinib + cetuximab	✖	●	✖	✖	✖
gefitinib	✖	✖	⊘	✖	✖
anlotinib hydrochloride, osimertinib	✖	✖	✖	✖	● (IV)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(T790M) c.2369C>T (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
icotinib hydrochloride, radiation therapy	✖	✖	✖	✖	● (IV)
bevacizumab (Shanghai Hengrui Pharmaceutical) + chemotherapy, bevacizumab + chemotherapy	✖	✖	✖	✖	● (III)
bevacizumab, atezolizumab, chemotherapy	✖	✖	✖	✖	● (III)
durvalumab, chemotherapy	✖	✖	✖	✖	● (III)
icotinib hydrochloride, chemotherapy	✖	✖	✖	✖	● (III)
osimertinib, chemotherapy	✖	✖	✖	✖	● (III)
sintilimab, bevacizumab (Innovent Biologics), chemotherapy	✖	✖	✖	✖	● (III)
toripalimab, chemotherapy	✖	✖	✖	✖	● (III)
apatinib + chemotherapy	✖	✖	✖	✖	● (II)
avitinib	✖	✖	✖	✖	● (II)
bevacizumab, osimertinib	✖	✖	✖	✖	● (II)
BPI-7711	✖	✖	✖	✖	● (II)
chemotherapy, ramucirumab	✖	✖	✖	✖	● (II)
D-0316	✖	✖	✖	✖	● (II)
durvalumab, tremelimumab, chemotherapy	✖	✖	✖	✖	● (II)
famitinib, HS-10296	✖	✖	✖	✖	● (II)
KN046	✖	✖	✖	✖	● (II)
nivolumab, ipilimumab	✖	✖	✖	✖	● (II)
osimertinib, osimertinib + chemotherapy	✖	✖	✖	✖	● (II)
tyrosine kinase inhibitors, radiation therapy	✖	✖	✖	✖	● (II)
ASK120067	✖	✖	✖	✖	● (I/II)
AZD4635 + oleclumab	✖	✖	✖	✖	● (I/II)
DZD-9008	✖	✖	✖	✖	● (I/II)
EMB01	✖	✖	✖	✖	● (I/II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(T790M) c.2369C>T (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
icotinib hydrochloride + chemotherapy + radiation therapy	✖	✖	✖	✖	● (I/II)
KP-673	✖	✖	✖	✖	● (I/II)
lazertinib	✖	✖	✖	✖	● (I/II)
U3-1402	✖	✖	✖	✖	● (I/II)
alisertib, osimertinib	✖	✖	✖	✖	● (I)
APG-1252, osimertinib	✖	✖	✖	✖	● (I)
CK-101	✖	✖	✖	✖	● (I)
ES-072	✖	✖	✖	✖	● (I)
everolimus + neratinib, neratinib + palbociclib, neratinib + trametinib	✖	✖	✖	✖	● (I)
FCN-411	✖	✖	✖	✖	● (I)
JNJ-61186372	✖	✖	✖	✖	● (I)
lazertinib, JNJ-61186372	✖	✖	✖	✖	● (I)
nazartinib, trametinib	✖	✖	✖	✖	● (I)
nivolumab, ipilimumab, radiation therapy	✖	✖	✖	✖	● (I)
osimertinib + radiation therapy, osimertinib	✖	✖	✖	✖	● (I)
osimertinib, necitumumab	✖	✖	✖	✖	● (I)
pirotinib	✖	✖	✖	✖	● (I)
SH-1028	✖	✖	✖	✖	● (I)
TP-0903	✖	✖	✖	✖	● (I)
TQB3456	✖	✖	✖	✖	● (I)
tyrosine kinase inhibitors, tyrosine kinase inhibitors + chemotherapy	✖	✖	✖	✖	● (I)
YK-029A	✖	✖	✖	✖	● (I)
YZJ-0318	✖	✖	✖	✖	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated 👎 Not recommended 🛡 Resistance

FDA information is current as of 2020-02-28. For the most up-to-date information, search www.fda.gov.

EGFR exon 19 deletion

● osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-12-19 **Variant class:** EGFR exon 19 deletion

Indications and usage:

TAGRISSO® is a kinase inhibitor indicated for

- the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdf

EGFR p.(T790M) c.2369C>T

● osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-12-19 **Variant class:** EGFR T790M mutation

Indications and usage:

TAGRISSO® is a kinase inhibitor indicated for

- the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdf

Current NCCN Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated 👎 Not recommended 🛡 Resistance

NCCN information is current as of 2019-11-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

EGFR exon 19 deletion + EGFR p.(T790M) c.2369C>T

● afatinib + cetuximab

Cancer type: Non-Small Cell Lung Cancer **Variant classes:** EGFR T790M mutation & EGFRi sensitizing mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Progression after receiving erlotinib, afatinib, dacomitinib, or gefitinib and systemic therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR exon 19 deletion

● osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

● bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Squamous Non-Small Cell Lung Cancer; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR exon 19 deletion (continued)

erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy) (Preferred)
- Progression on osimertinib (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

NCCN Recommendation category: 2B

Population segment (Line of therapy):
- Non-Squamous Non-Small Cell Lung Cancer; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Useful in Certain Circumstances)
- Non-Squamous Non-Small Cell Lung Cancer; Sensitizing EGFR mutation discovered during first-line systemic therapy (First-line therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR exon 19 deletion (continued)

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Newly diagnosed (Not specified)
- Non-Small Cell Lung Cancer; Leptomeningeal and Spine metastases (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

alectinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

brigatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

ceritinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR exon 19 deletion (continued)

crizotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

lorlatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

pembrolizumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

Other criteria: CD274 overexpression

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "A small study suggests that single-agent pembrolizumab is not effective as first-line therapy in patients with metastatic NSCLC and EGFR mutations, even those with PD-L1 levels more than 50%."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(T790M) c.2369C>T

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression on erlotinib (+/- ramucirumab or bevacizumab), afatinib, gefitinib or dacomitinib (Subsequent therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression with symptomatic brain metastases (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

---

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Recurrent disease; Use agents active against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

---

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Newly diagnosed (Not specified)
- Non-Small Cell Lung Cancer; Leptomeningeal and Spine metastases (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

---

pembrolizumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

Other criteria: CD274 overexpression

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "A small study suggests that single-agent pembrolizumab is not effective as first-line therapy in patients with metastatic NSCLC and EGFR mutations, even those with PD-L1 levels more than 50%."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(T790M) c.2369C>T (continued)

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "The most common known mechanism is the acquisition of T790M (which is a secondary mutation in EGFR), which renders the kinase resistant to erlotinib, gefitinib, dacomitinib or afatinib."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "The most common known mechanism is the acquisition of T790M (which is a secondary mutation in EGFR), which renders the kinase resistant to erlotinib, gefitinib, dacomitinib or afatinib."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR tyrosine kinase inhibitor

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

Summary:

NCCN Guidelines® include the following supporting statement(s):
- "EGFR p.Thr790Met (T790M) is a mutation associated with acquired resistance to EGFR TKI therapy and has been reported in about 60% of patients with disease progression after initial response to erlotinib, gefitinib, or afatinib."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "The most common known mechanism is the acquisition of T790M (which is a secondary mutation in EGFR), which renders the kinase resistant to erlotinib, gefitinib, dacomitinib or afatinib."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(T790M) c.2369C>T (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):

- "The most common known mechanism is the acquisition of T790M (which is a secondary mutation in EGFR), which renders the kinase resistant to erlotinib, gefitinib, dacomitinib or afatinib."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

Current EMA Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated 👎 Not recommended 🛡 Resistance

EMA information is current as of 2020-02-28. For the most up-to-date information, search www.ema.europa.eu/ema.

EGFR exon 19 deletion

● bevacizumab (Allergan) + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-11-12 **Variant class:** EGFR exon 19 deletion

Reference:

https://www.ema.europa.eu/en/documents/product-information/mvasi-epar-product-information_en.pdf

● bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-20 **Variant class:** EGFR exon 19 deletion

Reference:

https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf

● erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-25 **Variant class:** EGFR exon 19 deletion

Reference:

https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf

● osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-25 **Variant class:** EGFR exon 19 deletion

Reference:

https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf

EGFR p.(T790M) c.2369C>T

● osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-25 **Variant class:** EGFR T790M mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf

EGFR p.(T790M) c.2369C>T (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-05-28 **Variant class:** EGFR T790M mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf

Current ESMO Information

In this cancer type | In other cancer type | In this cancer type and other cancer types | Contraindicated | Not recommended | Resistance

ESMO information is current as of 2019-11-01. For the most up-to-date information, search www.esmo.org.

EGFR exon 19 deletion

atezolizumab + bevacizumab + carboplatin + paclitaxel

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR exon 19 deletion

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Metastatic Non-Squamous; Magnitude of Clinical Benefit Scale Score version 1.1 score: 3 (First-line therapy)
- Metastatic; PS 0-1; Without contraindications to immunotherapy after targeted therapies have been exploited (Second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Advanced stage; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

gefitinib + carboplatin + pemetrexed

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):
- Advanced stage (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR exon 19 deletion (continued)

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 3 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

bevacizumab + gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 3 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR p.(T790M) c.2369C>T

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR T790M mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Stage IV; Resistance to first-/second generation EGFR TKI; If not received previously; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 4 (Second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

Signatures

Testing Personnel:

2020.06.05
10:12:24 +08'00'

Laboratory Supervisor:

2020.06.05
10:12:39 +08'00'

Pathologist:

2020.06.05
10:12:55 +08'00'

References

1. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985 Sep 6;229(4717):974-6. PMID: 2992089
2. ErbB Receptors and Cancer. Methods Mol. Biol. 2017;1652:3-35. PMID: 28791631
3. Gutierrez et al. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 2011 Jan;135(1):55-62. PMID: 21204711
4. Pines et al. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010 Jun 18;584(12):2699-706. PMID: 20388509
5. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
6. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013 Oct;45(10):1113-20. PMID: 24071849
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4. PMID: 22588877
8. da et al. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. PMID: 20887192
9. Arcila et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 2013 Feb;12(2):220-9. PMID: 23371856
10. Kobayashi et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23. PMID: 26206867
11. Yasuda et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18;5(216):216ra177. PMID: 24353160
12. Chiu et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol. 2015 May;10(5):793-9. PMID: 25668120
13. Karachaliou et al. KRAS mutations in lung cancer. Clin Lung Cancer. 2013 May;14(3):205-14. PMID: 23122493
14. Brennan et al. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-77. PMID: 24120142
15. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576-82. PMID: 25631445
16. Mitsudomi et al. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010 Jan;277(2):301-8. PMID: 19922469
17. Ji et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006 May 16;103(20):7817-22. PMID: 16672372
18. Gazdar. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009 Aug;28 Suppl 1:S24-31. PMID: 19680293
19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf
21. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf
22. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdf
23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf
24. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf
26. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
27. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]